Efficient solutions for less-invasive genetic analyses
Efficient solutions for less-invasive genetic analyses
BiopSensen offers solutions and services for liquid biopsy monitoring of cancer. When the selection of available medications are increasing, more frequent monitoring helps the oncologists to respond more quickly, if the therapy is not satisfactory or if possible drug resistance is raised. As a result, the patient will receive the correct treatment faster. Cancer medications are often very expensive, in addition, cancer medications are either really effective or not working at all. That is why it is really important to get the medication right as soon as possible. Therefore, screening for cancer with BiopSense is a very effective way to improve the quality of cancer treatments and reduce costs.
Sample transfer is a bottleneck for the global availability of liquid biopsy services and also impedes the business of our company. Therefore BiopSense develops automated extraction and transfer cartridge of blood-based biomarkers (DNA, RNA, cells, proteins). This enables frequent sample acquisition and analysis, as well as facilitates the expansion of the international liquid biopsy service business across borders and continents, independently of the laboratory workforce situation in the customer hospitals or conditions of the sample transfer.
BiopSense is medtech company founded in Jyväskylä, Finland. BiopSense was born from a research project at the University of Jyväskylä. We have a diverse and committed core team with extensive expertise from nanosciense to oncology. We co-operate with Business Finland and Startup Factory of Jyväskylä. Please feel free to contact us if you are interested in hearing more from us.
CEO
Business and technology development
veli-mikko.puupponen@biopsense.com
+358 406587785
Scientific advisor
DNA technologies
marja.tiirola@biopsense.com
Medical Director
Chief physician, Oncology
Medical management
juha.kononen@biopsense.com
You can contact us directly, or leave a callback request
with your phone number to the message box below.
BiopSense Oy has received funding from the European Union’s Horizon Europe programme under grant agreement No 101057941. Views and opinions expressed are however those of the author(s) only and do not necessarily reflect those of the European Union or European Innovation Council. Neither the European Union nor the granting authority can be held responsible for them.